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Environmental contamination with pharmaceuticals is widespread, inducing risks to both human health
and the environment. This paper explores potential societal solutions to human and veterinary phar-
maceuticals in the aquatic environment. To this end, we adopt transition research’s multi-level
perspective framework, which allows us to understand the dynamics underlying pharmaceutical emis-
sions and to recognize social and technical factors triggering change. Our qualitative analysis is based on
data collected through literature research and interviews with actors from pharmaceutical industry, the
health and agricultural sector. The research aims at identifying potential future solutions including re-
quirements for as well as barriers to pathways leading to these solutions and describing the role of key
actors involved. The three alternative societal solutions identified are: 1) accepting pharmaceuticals in
the environment - substantial changes to the system are not required; 2) reconfiguring the current
system by implementing various innovations that reduce pharmaceutical emissions; 3) fundamentally
changing the current system to (largely) avoid pharmaceutical emissions. The paper further elicits so-
cietal, financial, organizational, regulatory and technological requirements that can facilitate imple-
mentation of these solutions. This work is novel as it constitutes a systemic view on all stages of the
pharmaceutical lifecycle, comprehensively synthesizing options and measures along the entire lifecycle
into societal solutions that are framed as transition pathways. Deriving societal solutions from key actor’s
perspectives is innovative and provides insights to reflect on choices societies are going to have to make
regarding pharmaceuticals in the environment.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Around the globe, pharmaceuticals along with their metabolites
and transformation products are frequently found in the aquatic
environment (Aus der Beek et al., 2015). Besides ecotoxicological
effects on different plant, fish and bird species emerging from
pharmaceutical exposure (Aus der Beek et al., 2015), pharmaceu-
tical residues are found in drinking water (Leung et al., 2013) andulty of Engineering Technol-
x 217, 7500, AE Enschede, the
r Ltd. This is an open access articlfood products (Boxall et al., 2006). Furthermore, antimicrobial
resistance associated with the presence of antibiotics in the envi-
ronment is a global threat (Singh et al., 2019). Since both, human
and veterinary pharmaceutical use continue to increase globally
(due to population growth, rising per capita consumption and
growing livestock) the issues are likely to exacerbate (Klein et al.,
2018; Van Boeckel et al., 2015).
Pharmaceuticals are potentially emitted into aquatic environ-
ments along each step of their lifecycle - from manufacturing via
application to disposal. At manufacturing sites, pharmaceutical
discharges can be emitted directly to water bodies (Larsson, 2014).
After consumption, fractions of administered pharmaceuticals are
excreted (Winker et al., 2008). Pharmaceuticals excreted by
humans are typically discharged into sewers first, before enteringe under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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excreted by animals reside in manure that can be spread on agri-
cultural land as fertilizer (Kümmerer, 2008a). From there they can
enter the aquatic environment through runoff or leaching (Sarmah
et al., 2006). Finally in the disposal stage, inaccurate discarding
practices can lead to pharmaceutical pollution of freshwaters
(Vollmer, 2010).
Aus der Beek et al. (2015) compile data from numerous studies
that proof pharmaceutical presence in different aquatic media.
Depending on the compound, geographical location and emission
source, hotspots for pharmaceutical concentrations have been
identified at e.g. manufacturing sites (Larsson, 2014), wastewater
discharges from households or hospitals (Aus der Beek et al., 2015)
and areas with intensive livestock industry (Menz et al., 2015).
Pharmaceutical’s individual physicochemical, pharmacological
and biological properties e and therefore their environmental be-
haviours e vary widely (Kümmerer, 2008a). With several thousand
pharmaceutical substances authorized to the European market
(European Medicines Agency, 2020; Kümmerer, 2008a), environ-
mental impact of the manifold substances is extremely diverse.
Previous research focussed on environmental, chemical and
technological aspects of pharmaceuticals in the environment (PIE),
rather than societal ones (Daughton, 2016). Frequently discussed
solutions to PIE focus on removing pharmaceuticals from waste-
water through improved treatment technologies. These have
proven to effectively remove a variety of pharmaceuticals, where
often the degree of removal depends on the intensity or reaction
time of the method (e.g. for ozonation or activated carbon)
(Mansour et al., 2018; Paucar et al., 2019; Szabova et al., 2020).
Nevertheless, this focus is criticized in the scientific discourse, as
until now no individual end-of-pipe technology has proven to
sufficiently eliminate all substances (Kümmerer, 2008b; Voigt et al.,
2020), there is no adequate knowledge about (long term) ecotoxi-
cological risks for remaining effluent concentrations even if
removal rates are high (Angeles et al., 2020), and doubts are raised
over it’s added costs, feasibility and reasonability (Eggen et al.,
2014; Kosek et al., 2020; Voigt et al., 2020). Moreover it is unclear
if current technologies can remove prospectively developed sub-
stances or compounds that are created during treatment processes
(Kosek et al., 2020; Kümmerer, 2008b). Besides, technological end-
of-pipe solutions do not address the issue of PIE over the entire
lifecycle and neglect approaches that relate to societal aspects of
how pharmaceuticals are prescribed, used, and disposed.
We argue that including the societal dimension into the dis-
cussion is essential, as the way society utilizes pharmaceuticals
drives environmental emissions along the entire pharmaceutical
lifecycle. Society must find a way to deal with trade-offs between
improving human and animal health through pharmaceutical use
and environmental sustainability.
To date, comprehensive studies that include societal embedding
of proposed solutions are lacking. In particular, there is a clear
knowledge gap in addressing appropriate institutional settings,
economic, cultural and behavioural incentives and actors’ collabo-
rations towards successful strategies.
In this paper we explore alternative societal solutions to deal
with PIE by using the multi-level perspective (MLP), a framework
that conceptualizes patterns for system change at different
analytical levels (Geels, 2011). A societal function (in this case
pharmaceutical supply and use) is performed by a socio-technical
system, an established configuration. Changes of the existing sys-
tem occur due to developments and interplay at the different levels.
We perform actor interviews and enrich as well as cross-check
these with comprehensive literature to delineate different future
solutions, following MLP theory. The core of the paper is to inspect
actors’ perceptions of the situation regarding PIE and identify their2
understanding and visions on solutions, their ideas regarding actor
roles, and their opinion on requirements to implement solutions.
Further, we explore what barriers actors foresee for each solution.
Interviews were conducted in Germany and the Netherlands. While
the research’s scope is on the aquatic environment, the topic was
framed towards interviewees as PIE in general.
2. Theoretical framework, methods and data
2.1. Multi level perspective framework
This study uses the MLP to describe and analyse alternative
societal solutions to PIE. The framework originates from transition
research, which investigates system changes over time. MLP con-
siders the setting in which transitions occur as a socio-technical
system (Geels and Kemp, 2012), which is framed as the pharma-
ceutical lifecycle from development to environmental emission in
this study.
Embedded in the socio-technical system, the MLP differentiates
between three analytical levels landscape, regime and niche (Geels,
2011). A conceptual overview of the MLP, including the contextu-
alization of the pharmaceutical lifecycle, is illustrated in Fig. 1.
The regime level is assigned to the space where actors interact,
maintaining the setting of the socio-technical system according to
anchored rules that determine the functioning of the system. It
represents a complex arrangement of social groups and actors
related to the system’s societal function (Holtz et al., 2008). In this
researchwe specifically focus on actor groups related to the societal
function of pharmaceutical supply. Niches refer to emerging in-
novations that might prevail (Geels and Kemp, 2012). In the context
of pharmaceutical lifecycle, both technical and non-technical in-
novations reducing PIE are considered. The landscape is the exog-
enous context within the socio-technical system including the
natural environment, material components like infrastructure and
societal components such as legal structures, cultural believes and
political trends (Geels, 2002). With the core of this research being
on alternative societal solutions to PIE, we focus on the societal
components of the landscape level by describing and interpreting
policy developments in the EU along with Germany and the
Netherlands as cases where regime actors were interviewed. In
addition, we outline landscape changes mentioned by the inter-
viewed regime actors.
Geels (2011) and Geels and Schot (2007) describe transitions as
shifts from one regime to another whereby the landscape and niche
levels are derived concepts in relation to the regime. Landscape
dynamics creating pressure on the regime and occurring in-
novations at niche level can create momentum for a transition
(Geels and Schot, 2007). This research uses the MLP to structure
what alignments of changes at the different levels can lead to
distinct futures regarding PIE. A detailed description of these
pathways is presented in the SI.
2.2. Data collection
Data from regime actors was collected through 15 semi-
structured interviews. Even though this research investigates the
system of the pharmaceutical lifecycle as a whole, interviewees
were specifically selected from pharmaceutical industry, the
healthcare and agricultural sector as these are considered to play a
pivotal role in the pharmaceutical supply as well as in a potential
transition process. The participants were selected after the princi-
ples focus group and snow-ball sampling as outlined by Reed et al.
(2009); this is described in the SI. The interview was clustered into
six sections: (i) participant background; (ii) today’s situation and
problem description regarding PIE; (iii) future and potential
Fig. 1. Conceptual overview of the Multi-Level Perspective illustrating the three analytical levels landscape, regime and niches of the socio-technical system in context of the
pharmaceutical lifecycle, adapted from Geels (2002).
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level for potential solutions; (v) responsibilities for potential solu-
tions; (vi) critical reflection on solutions. The interviewmanuscript
can be found in the SI.
Pertinent literaturewas studied to gain insight on developments
at niche, regime and landscape level, complementing and cross-
checking interview data. This resulted in an inventory of existing
niche innovations, an outline of current regime dynamics and a
description of ongoing societal landscape changes.
2.3. Interview analysis
All interviews were transcribed non-verbatim and coded for
qualitative analysis with assistance of atlas.ti software. Codes were
created upon the different sections outlined under 2.2. We
extracted code reports to thematically analyse today’s situation as
well as alternative societal solutions to PIE. To delineate these, the
theory of transition pathways by Geels and Schot (2007) was fol-
lowed (see SI). Each interview contributed to sketch alternative
future regimes, whereby each future regime is based on input from
multiple interviewees and from literature. As the study is qualita-
tive, we do not weigh alternative solutions, but rather elicit actors’
perspectives on different options and pathways.
3. Results
3.1. The current socio-technical system of the pharmaceutical
lifecycle
3.1.1. Landscape changes affecting pharmaceuticals in the
environment
First legal steps concerning PIE were introduced by the EU in
1995 when requesting environmentally relevant information for
market authorization of new pharmaceutical products. Nonethe-
less, only in 2005 information requirements were specified,3
avoiding the previously insufficient environmental risk assess-
ments (ERA) (Wennmalm and Gunnarsson, 2010). In case of ex-
pected high environmental impacts, legislation differentiates
between human and veterinarian pharmaceuticals. Authorization
of the former is not affected by high environmental risk as EU
guideline 2001/83/EG states this cannot impact the risk-benefit
consideration (Koschorreck and Hickmann, 2008; Parliament and
Comission, 2001). Still, measures to minimize environmental risks
should be taken, if possible. A high environmental risk from vet-
erinary pharmaceuticals can obstruct market release in two cases:
environmental risks cannot be minimized and a comparable com-
pound is available (Koschorreck and Hickmann, 2008). These
landscape developments show that human health is prioritized
over environmental health. However, animal health is not generally
prioritized over environmental health.
The first grounds for European water legislation emerged in the
1970s with e.g. water quality standards for drinking water
abstraction. An important transformation took place decades later
by implementing the Directive 2000/60/EC, commonly known as
Water Framework Directive (WFD). Implemented in 2000, theWFD
represents a fundamental guideline for European water manage-
ment, specifically considering pollution prevention (European
Commission, 2016b). However, pharmaceutical pollution is not
explicitly mentioned. To complement EU water management, a
watch-list for emerging water pollutants was implemented under
the WFD in 2015, intended to provide targeted, high-quality in-
formation on substances of concern (European Commission,
2016a). The list is iteratively evaluated, whereby substances are
added and removed. The watch-list comprised the first link of
pharmaceutical pollution to EU water legislation. Barbosa et al.
(2016) conclude that despite legislative developments under the
WFD, legal discharge limits for pharmaceuticals are lacking.-
Whereas the WFD targets freshwaters’ quality status independent
of the emission sources, water pollution through pharmaceutical
production is additionally addressed in Directive (2010)/75/EU
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of environmental limit values when giving industrial permits
(European Commission, 2019b). Given the non-existence of EU
limit concentrations for pharmaceuticals, thesemust be established
by the permitting authority in coherence with experts’ best avail-
able technique reference document. Environmental inspections are
implemented as a control mechanism (European Commission,
2019b). Additionally, in 2013 the EU enforced that all imported
pharmaceutical ingredients have to be produced with respect to
good manufacturing practices by EU standards (European
Commission, 2012).
Addressing PIE for the first time from a lifecycle perspective in
policy, the European Commission published a strategic approach to
PIE in 2019. The approach provides different areas of action along
the pharmaceutical lifecycle, to be followed by the EU and it’s
member states (European Commission, 2019a). Nevertheless, the
approach neither presents discharge limits nor quantifiable targets
for proposed actions. On national level, the Dutch government
developed a chain approach to address PIE from a lifecycle
perspective, releasing an implementation program in 2018. The
program outlines different actions to reduce human pharmaceu-
tical emissions. Veterinary pharmaceutical emissions are not (yet)
part of the approach (Government of the Netherlands, 2019). In
Germany, no governmental policy exclusively tackles PIE. However,
governmental bodies initiated a stakeholder dialog that developed
a strategy to implement measures reducing trace pollutants in
waters (BMU and UBA, 2019). Policy developments along with
other landscape changes mentioned by regime actors are displayed
in Table 1.
3.1.2. Regime dynamics affecting pharmaceuticals in the
environment
Pharmaceutical development and manufacturing: The
required ERA for market authorization (section 3.1.1) forces regime
actors to consider environmental aspects in pharmaceutical
development. Nevertheless, interviewees described potential
neglection of the total environmental loads through the product-
based approach and the lack of follow-up after authorization as
shortfalls of the existing ERA. The pharmaceutical developing
sector was mentioned to give priority to human over environ-
mental wellbeing. Likewise, in ERA legislation environmental risks
cannot lead to exemption from authorisation. Regime actors
explained that drivers for pharmaceutical development are the
discovery of substances resulting in first-ever treatment of dis-
eases, and of products preferable over existing pharmaceuticals,
e.g. fewer side effects. Economic interest significantly drives the
development of new pharmaceuticals, as mentioned for antibiotics
by various interviewees. Little research is conducted to develop
new antibiotics, which would likely be classified as reserve medi-
cation in case of patients’ resistance towards common antibiotics.
This classification potentially results in prescription restrictions,
limiting profit margins irrespective of development costs. The lat-
est AMR industry alliance report describes a challenging overall
economic environment for researching companies and proposes
financial incentives from governments as a solution (AMR IndustryTable 1
Landscape changes determined through regime actor interviews.
Landscape element Influential changes
Policy Regulative developments regarding P
Demographics Aging population in Europe increases
Migration Increasing medicine use due to re-in
Societal trend Societal pressure to decrease animal
Societal trend Society demands animal production
4
Alliance, 2020).
Environmentally beneficial dynamics of the pharmaceutical
developing sector cover vaccine developments or the recent focus
on biopharmaceuticals. Alongside, Taylor (2016) describes syn-
ergies between drug design criteria and positive environmental
significance, e.g. full oral adsorption leading to less excreted frac-
tions. Further, regime actors agreed that the sector respects the
environmental relevance of pharmaceuticals, also because the topic
was recognized as highly media-effective and therefore politically
relevant.
The relevance of image was as well mentioned for the
manufacturing industry. One interviewee described that scoring
well in environmental rankings is positively received by share-
holders. Further, participants portrayed the industry’s increasing
awareness of their responsibility after several reports were
doubting responsible manufacturing. However, pharmaceutical
manufacturing happens along global production chains, compli-
cating implementation and control of ubiquitous sustainability
criteria. On global level, industrial discharge limits are rare
(Larsson, 2014). Regulations exist within the EU (section 3.1), but
most pharmaceutical manufacturing takes place outside Europe
(Larsson, 2014). Interviewees from the health and agricultural
sector were strongly concerned about pollution from
manufacturing, especially outside the EU. Nevertheless, techno-
logical developments for industrial wastewater treatment exist
along with self-regulation by the industry (AMR Industry Alliance,
2020; Larsson, 2014).
Human health sector: The sector’s core priority is curing
humans, commonly using allopathic medicine. According to regime
actors, medicine use is promoted by pharmaceutical industry,
governments, doctors’ and pharmacists’ organization, denoting
non-transparent dynamics. One interviewee explained that critical
considerations exist on the functioning of certain pharmaceuticals
(where effects are statistically significant, but not clinically rele-
vant), but is generally not shared by doctors. Another identified
mechanism supporting medicine use is the patients’ amenity to
prefer medical prescriptions over behavioural change to improve
well-being. This is similar to humans endorsing environmental
cautiousness, but not acting accordingly themselves - a value-
action gap well-known in environmental research (see e.g.
Kollmuss and Agyeman (2002)). Moreover, medical staff is not
intrinsically aware of PIE, misperceptions towards wastewater
treatments’ effectiveness exist and dealing with PIE is perceived to
surpass their responsibility. Nevertheless, regime actors also
observed emission limiting dynamics within the health sector. They
described increasing media-reporting about PIE, raising awareness
among staff and patients. Specifically for the Netherlands, a trend
towards less surgeries and de-prescribe medicines was observed.
Pharmaceutical leftovers potentially leading to environmental
emissions exist in healthcare institutions and private households
(Daughton and Ruhoy, 2011). Interviewees mentioned prescription
routines leading to leftovers and criticised the absence of unified,
safe disposal systems.
Agricultural sector: Pharmaceutical use in livestock is practiced
to avoid and treat diseases in animals used for animal production.IE
medicine use
troduction of previously controlled diseases
numbers (specifically mentioned for the Netherlands)
under high animal welfare standards, increasing use of certain pharmaceuticals
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motion and increased production efficiency (Bloom, 2004). In the
EU, growth promotion with pharmaceuticals was prohibited in
2006 (European Commission, 2005). Where economic competi-
tiveness is a main driver for the agricultural sector (Sarmah et al.,
2006), a more efficient production leads to more financial profit
and stability. Limiting disease spread and having healthy animals is
a key to this strategy (Sarmah et al., 2006). Regime actors described
different dynamics analogous to efficiency, driving environmental
emissions of pharmaceuticals. One of these is the economic trade-
off between treating diseases once they occur and prevention
through vaccines or management practices. Another is the eco-
nomic decision to preventively treat the entire herd to avoid dis-
ease spreading once an individual is infected. Sarmah et al. (2006)
closely link big animal numbers on farms to medicine use con-
trolling disease spread. However, interviewees indicated that con-
ditions and treatment practices differ among animal types and
farming systems, causing differences among farms. Yet, there is no
information available on pharmaceutical use intensity differenti-
ated between farming systems, farm sizes or animal types,
impeding comparisons. One participant explained that antibiotic
use on organic farms is highly restrictive, as it is also regulated by
the EU (Ivemeyer et al., 2012), but organic farm animals spendmore
time outside, making them more vulnerable to certain health is-
sues. Another trend described is increasing farm productivity as
farm size and degree of specialization grows. Interviewees
observed the phenomenon that regional hotspots of large, highly
specialized farms cause high animal densities and pollution po-
tential where the animal products are exported from that region.
Regime actors were also critical on the fact that veterinarians
prescribe and sell pharmaceuticals providing them a financial
prescription incentive.
Discussions of veterinary pharmaceuticals in the environment
strongly focus on antibiotics. Several regulations, e.g. reporting of
medicine application, is only required for antibiotics, possibly
causing overlooking the relevance of other substance groups.
3.1.3. Niche innovations
Niches where innovations reducing PIE occur developed along
the entire pharmaceutical lifecycle. Fig. 2 illustrates existing niche
innovations with overall descriptions per innovation identified. For
some niche innovations multiple approaches have been discovered
(e.g. different pharmaceutical removal technologies are summa-
rized as “advanced wastewater treatment”). An overview of niche
innovations, including alternative approaches is presented in the SI.
3.2. Potential societal solutions
Three alternative societal solutions were identified: 1) Accept-
ing pharmaceuticals in the environment as a reproduction process
without regime shift; 2) Implementing niche innovations in
different sectors as a reconfiguration pathway where a new regime
emerges from the existing regime, hereby regime actors remain; 3)
A system change as a de-alignment of the current regime, poten-
tially with re-alignment of an entirely new regime. Fig. 3 gives an
overview of the three identified solutions, embedding case-specific
items into the concepts of different transition pathways.
Accepting pharmaceuticals in the (aquatic) environment:
From an environmental risk perspective, pharmaceutical sub-
stances bear identical risk as any other chemical. From an envi-
ronmental management viewpoint however, health benefits
distinguish pharmaceuticals from other chemicals (Taylor, 2016).
Regime actors reflect this opinion by describing that pharmaceu-
tical emissions are inevitably in guaranteeing human and animal
wellbeing. We therefore identified the first future solution as5
“accepting pharmaceuticals in the environment”, a reproduction of
the current regime. Especially regime actors of the pharmaceutical
industry and the human pharmaceutical sector pointed out that
society would always prioritise pharmaceutical use over their
environmental relevance. Consequently, they believe that the so-
cietal perception of pharmaceutical’s importance (section 3.2) will
not change, preserving existing regime dynamics. Other in-
terviewees were convinced that options to reduce pharmaceutical
use exist, but are not entirely avoidable due to serious diseases such
as cancer. Hereby, they suggested to follow a no-regret strategy,
where avoidable emissions are reduced without trade-offs. Re-
quirements mentioned for this approach are evidence on envi-
ronmental risk and knowledge about emission sources of
pharmaceuticals.
Implementing niche innovations: Interviewee statements for
this solution varied from individual innovations to broad sets of
measures for complementary or parallel implementation. An
overarching innovation mentioned by most participants is aware-
ness raising, involving education and knowledge transfer. Aware-
ness raising is perceived as relevant to increase public
understanding of the topic, but also to equip actor groups with
knowledge to implement other innovations. A comprehensive list
of awareness-raising elements and their requirements is given in
the SI.
The so-called green pharmacy is a frequently discussed
approach to PIE, which interviewees considered relevant as well.
Firstly, they referred to the design of new substances while
considering environmental biodegradability. Where pharmaceuti-
cals are stable within the target body fulfilling their function, they
degrade during wastewater treatment or in the environment
(Straub, 2016). Kümmerer (2019) describes different methods
resulting in more environmentally friendly b-blockers, antibiotics
and one cytostatic. Secondly, multiple regime actors suggested the
enhanced development of nature-based pharmaceuticals and
phytotherapeutics. Literature introduces these concepts as “benign
by nature” (Straub, 2016), where synthetically developed phar-
maceuticals are substituted by natural compounds not showing
environmental toxicity. One example is alkaline phosphatase, a
naturally-occurring enzyme preventing inflammations (Seinen and
Feil, 2019). Thirdly, participants mentioned new dosage forms
where the same effect is achieved with smaller substance amounts.
Pharmaceuticals with low bioavailability require high administered
doses to reach pharmaceutically active concentrations, leading to
large excreted fractions (Straub, 2016). So-called prodrugs are
inactive in their original form. After administration, prodrugs
metabolize and become pharmacologically active. This leads to
reduced doses, increased bioavailability and smaller excreted
fractions (Straub, 2016). Lastly, regime actors explained that vaccine
development can reduce pharmaceutical use and emissions.
Regarding drug authorization, one interviewee argued for
improving the existing ERA. Another participant pleaded to exclu-
sively authorize pharmaceuticals that proof to have more clinically
relevant effects than placebos and remove non-complying sub-
stances from the market.
Interviewees named a series of requirements to realize
development-related innovations:
 societal and sectoral demand
 research unbiased as to the result
 willingness by pharmaceutical industry
 new orientation of pharmaceutical industry
 financial and legislative governmental research support to
incentivise
 governmental enforcement
 enforcement by health insurance companies
Fig. 2. Pharmaceutical lifecycle from the development to disposal, and niche innovations (in hexagons) illustrating where they have an effect.
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Coherently with literature (Larsson, 2014), participants consid-
ered the reduction of emissions frommanufacturing alongsidewith
the implementation of environmental standards as essential for the
industry. This requires research-based standards and technologies
to safely dispose industrial pharmaceutical wastes or treat waste-
waters. To guarantee that manufacturers meet standards, one
participant suggested a “carrot and stick approach”: Incentivizing
and rewarding well-performing manufacturers on the one hand,
enforcing and sanctioning poorly-performing companies on the
other hand. Additionally, one interviewee suggested to move all
pharmaceutical production to Europe, where supposedly6
environmental requirements are stricter.
Another set of niche innovations targets the supply and use of
human pharmaceuticals. Participants agreed that pharmaceutical
use, thus emissions, can be reduced through lifestyle interventions
such as reducing weight, eating healthy, physical activity. Deffner
and G€otz (2008) likewise describe health-supporting measures to
reduce PIE arguing for prescribing and financially supporting these
through the health care system. Requirements for lifestyle in-
terventions found are:
 public education
 motivation among people
 promoting lifestyle interventions instead of pharmaceutical use
Fig. 3. Transition pathways for different societal solutions to pharmaceuticals in the environment (PIE), from top to down: 1) accepting PIE, 2) implementing niche innovations, 3)
system change. Adapted from Geels and Schot (2007).
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 regulatory measures on unhealthy products (taxing, restricting
accessibility)
Moreover, regime actors argued for the implementation of niche
innovations related to prescription and use of pharmaceuticals:
Changing prescription routines, using pharmaceuticals appropri-
ately, alternative treatments. A list describing detailed elements
and their requirements is presented in the SI. In Sweden, these
niches were adopted by the regime through environmental clas-
sification of pharmaceuticals, supporting practitioners to choose
alternative pharmaceuticals posing less environmental risk
(Ågerstrand et al., 2009).
Estimates on incorrectly disposed leftover pharmaceuticals
differ strongly (from 0% in Sweden to 92% in the U.S.) and contin-
uous monitoring about pharmaceutical discarding is lacking
(Vollmer, 2010). Numerous participants of this study see incorrect
disposal as an ongoing issue. They named smaller package sizes and
pharmaceutical recycling as innovations to reduce pharmaceutical
leftovers. For remaining leftovers, they stressed the need for safe
and ubiquitous disposal systems, advertised through public media
and pharmacies.
Moreover, regime actors mentioned that end-of pipe innovations
can contribute to this solution, whereby they differentiated between
decentral and central pollution control technologies. Decentral in-
novations covered installations in household toilets, wastewater
treatment at healthcare institutions or urine collection systems.
Several such ideas are elaborated in literature, e.g. contrast agent
collection with urine bags (Niederste-Hollenberg et al., 2018). In-
terviewees listed following requirements:
 technological developments for household installations
 focus on specific pharmaceuticals for urine collection
 urine collection must be feasible for patients
 case by case decisions about most suitable system
 innovation funding; decision on who covers costs
Centralized installations removing pharmaceuticals at munic-
ipal wastewater treatment plants are perceived as useful comple-
ments to source-oriented innovations. This approach has been
intensively researched e considering numerous technologies
including ozonation, activated carbon or membrane filtration
(Fr€ohlich et al., 2019; Homem and Santos, 2011) - and regionally
implemented, for instance in Switzerland (Eggen et al., 2014).
Furthermore, these technologies can be effective against metabo-
lites as well (Rúa-Gomez et al., 2012). Given high costs for these
technologies, regime actors suggested to focus on hotspots where
additional treatment is economically and ecologically useful. They
see necessity for funding schemes and propose ascertainment of
society’s willingness to pay.
Disease prevention was described relevant for the livestock
sector as well. Besides vaccines, health-supporting management
plays a significant role. Participants stressed the importance of
well-managed housing, food and hygiene. These measures are
likewise discussed in literature (Klatte et al., 2017). However, un-
derstanding the effectiveness of adjusted livestock management on
environmental pollution requires further investigation and costs
may hamper implementation (Evans et al., 2019). Requirements
mentioned by interviewees to overcome these aspects include:
 Knowledge by farmers
 Quality system for farmers
 Broad, coherent animal health data collection for better
knowledge on health management (e.g. animal health index)
 Novelties improving health management (e.g. housing)
8
 Investments on farms
 Higher prices for animal products
Other innovations proposed target the application of pharma-
ceuticals in livestock. We clustered these as illustrated in Table 2.
Manure treatment and improved soil management were named
as end-of-pipe innovations. Besides manure incineration (Derksen
et al., 2015), different treatment options such as heating, drying,
pasteurisation exist (Vidaurre et al., 2016). Despite these options
proposed in literature, interviewees named the development of
treatment methods along with loosening legal regulation on
manure processing as requirements for this innovation. Soil prop-
erties influence pharmaceuticals’ leaching and runoff potential
significantly (Sarmah et al., 2006), which is why optimized soil
management practices (soil cover, optimized organic content, high
root density) were described as beneficial. Knowledge about these
practices was named as a key requirement.
To avoid incorrect disposal of veterinary pharmaceutical left-
overs, one participant proposed that veterinarians collect leftovers
from farms and safely dispose them.
System change: De-alignment of the current system can occur
independently for the human and veterinary sector. For the agri-
cultural sector, different directions of system changes were brought
up by the interviewees (Fig. 4, including requirements). Rethinking
farming systems and reducing animal numbers are transitions,
where the current agricultural sector changes fundamentally.
Similarly, Lamine (2011) investigates transition pathways towards
ecologization of agriculture. The disappearance of livestock and the
ban of pharmaceuticals are transitions where most likely entire
sectors disappear.
System change concerning human pharmaceutical emissions
was also discussed among regime stakeholders. One participant
mentioned the ban of pharmaceuticals as a solution in case society
values environmental quality over individuals’ human health. This
is a rationale where environment as a common good is exploited by
pharmaceutical use and correlated pollution of individuals.
Giubilini (2019) follows a similar idea describing antibiotic resis-
tance as a tragedy of commons where consequences of individual’s
antibiotic use affect the entire society. Another interviewee pro-
posed a system change towards categorizing the necessity of
treatments distinguishing between life-endangering and lifestyle-
influencing situations. Consequently, a variety of currently com-
mon treatments would disappear in the future.
3.3. Responsibilities and barriers to potential solutions
Interview results indicate that a wide range of actors are
responsible for proposed solutions. Individual actors or sectors are
seen in charge of implementing innovations within their compe-
tence. Governmental institutions were given responsibility to
enforce regulations and control mechanisms. Society was described
as a driver that can demand and induce change This is a typical
landscape change potentially triggering a transition. Several par-
ticipants pointed out that simultaneous actions by different actors
are required to reach proposed solutions. A detailed list of actor
groups that regime actors see responsible for the implementation
of solutions is presented in the SI.
For the solutions ‘implementing niche innovations’ and ‘system
change’ regime actors described numerous barriers. Some are
specific barriers to individual innovations or requirements; others
are overarching hurdles that hinder proposed change. In our
analysis, we retrieved financial, knowledge, societal, cultural, re-
sponsibility, regulatory, organizational and technological barriers
to proposed solutions. A comprehensive overview of barriers is
given in the SI.
Table 2
Niche innovations targeting pharmaceutical use in livestock plus requirements.




Restricting substances proven to cause human or environmental health
issues
Precautionary prohibition of substances not proven to have no




Using reduction potential  Farmers’ and veterinarians’ willingness to change routines
 Not paying veterinarians for selling medicine, but for keeping animals
healthy and for their know-how
Extend benchmarks and measures from antibiotics to all
pharmaceuticals
 enforcement
Breed more robust animals to decrease use
Changing application
form




 knowledge and willingness by veterinariansHomeopathic therapy
Natural feed supplements reducing pharmaceutical use
Fig. 4. Directions of system changes and their requirements as societal solutions to veterinary pharmaceuticals in the environment, resulting of stakeholder interviews.
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4.1. Reflection on identified solutions
As checking of results from actor interviews against the existing
literature was conducted in the results section, this chapter criti-
cally reflects on the pathways of the identified solutions in addition
to the results presented.
An established regime of pharmaceutical provision, supply and
use is in place. Whilst the human pharmaceutical sector shows
lock-ins due to focus on human health over environmental health,
the veterinary pharmaceutical sector appears locked in because of
rooted (economic) structures. Despite the existence of an estab-
lished regime, pressuring landscape changes to address PIE
alongside with various niche developments were identified. Still,
niche innovations are not yet adopted at large scale due to multiple
barriers.
Accepting PIE is one identified solution, prospectively not or
insignificantly reducing emissions. Expectably, the regime in place
is stable, established routines maintain due to lack of societal
landscape changes and non-adaptation of innovations. A transition
of the socio-technical system is not anticipated. Considering global
predictions of rising pharmaceutical use, this solution poses
continuous, potentially increasing risk for environmental and hu-
man health. This is a contradiction to international agreements
such as UN’s sustainable development goals (United Nations, 2020)
or the strategic approach to pharmaceuticals in the environment by
the EU (European Commission, 2019a). Furthermore, it interferes
with intergenerational equity. Natural resources are exploited by
the current society at the cost of future generations.
Implementing innovations as a solution to PIE covers numerous
individual aspects which need simultaneous development to cap-
ture the diverse substances and emission pathways. Given their
extensive spectrum, emissions are probably reduced, but not
avoided as literature indicates the lack of widespread impact of
measures (e.g. Straub (2016)). While regime dynamics transform
for this solution, the regime of pharmaceutical life cycle and asso-
ciated actor groups prevail. To achieve this reconfiguration of the
existing regime, several barriers, typical lock-in mechanisms
(Geels, 2011), have to be overcome (see SI).
A system change can lead to the avoidance of PIE. We identified
several types of system change for the human and veterinary
pharmaceutical sectors. While somewill change or abandon certain
regime groups, likely to result in a reduction of PIE, others are more
fundamental, resulting in disappearance of entire sectors and
emission avoidance. Both constitute a transition where the societal
importance of human pharmaceutical use and the consumption of
animal products change fundamentally.
Following transition pathway theory, we identified three inde-
pendent solutions. However, elements of different solutionsmay be
combined, e.g. accepting PIE for specific cases, developing green
pharmaceuticals for human treatment and abandoning the live-
stock sector.
Setting the three solutions in context of ongoing landscape
changes, regime dynamics and niche developments (as outlined in
sections 3.1.1 to 3.1.3), trends clearly push towards implementing
niche innovations. Landscape changes on policy level aim at
accelerating innovation adoption, plus niche innovations are
increasingly researched. Regime actors indicated their willingness
to adopt various niche innovations, if feasible in terms of avail-
abilities, costs, regulations and other requirements (see 3.3).
Furthermore, several innovations reducing PIE have been imple-
mented already, according to the regime actors.
Several elements investigated in this research, were discussed
and evaluated in previous studies. However, none of these studies10consider different options society has as we do in this research. It is
novel to analyse the current system with ongoing changes and
explore potential future solutions from there.
4.2. Limitations of the study
Conducting this study in a European context generated results
potentially not universally applicable. Pharmaceutical use patterns
vary widely, leading to globally diverging situations (Klein et al.,
2018). Additionally, socio-technical systems differ among regions
(Coenen et al., 2012). Distinct niche, regime and landscape levels e
e.g. different legal frameworks (Maron et al., 2013), wastewater
systems (Malik et al., 2015), socio-cultural values of livestock pro-
duction (Thornton, 2010) - restrict global implementation of pro-
posed solutions. Consequently, requirements for solutions might
differ as well. Yet, the research describes a set of solutions providing
universal directions even if not all aspects are directly transferable
to all world regions.
The research considers the pharmaceutical lifecycle for human
and livestock use, excluding pharmaceutical emissions from e.g.
aquaculture or orcharding industry (Gaw et al., 2014; McKenna,
2019). Moreover, interviews were limited to regime actors from
sectors related to pharmaceutical supply. By defining this scope, we
neglect other actor groups being part of the regime in a broader
sense, such as patients or water authorities. We recommend that
future research enlarges this pool of actor groups. Further, a bias
might exist through participant selection and interviewee view-
points. Participants were mostly contacted through sector-
representing organizations. Even though we stressed special in-
terest by interviewees is not required, (unintentional) selection of
actors interested in PIE might have occurred. Consequently, this
research bases on interviewees’ perceptions, which are valid, but
not exclusive. More or other dynamics than those captured through
the interviews, might exist.
Regime actors described solutions from their viewpoint of to-
day’s situation. Some considered future predictions such as de-
mographics. The future is uncertain, however, if conditions, thus
landscape, change fundamentally, so may perspectives on solu-
tions. Thornton (2010) described an emerging global pandemic as
such incident.
This qualitative study presents alternatives without quantita-
tively assessing their consequences in terms of economic, societal
or environmental effects, which should become subject of further
research.
5. Conclusion
Different societal solutions to deal with PIE were identified by
investigating the pharmaceutical lifecycle through actor interviews
and literature, using the MLP framework and it’s theory on transi-
tion pathways: 1) accepting pharmaceuticals in the environment,
2) implementing niche innovations, 3) system change. They illus-
trate a wide spectrum of futures in terms of pharmaceutical
emissions, regime dynamics and societal changes. Accepting PIE
does not require changing the current regime, but pharmaceutical
pollution will at best remain, but likely worsen, considering global
trends. However, we found it is more likely that a range of in-
novations is going to be implemented as innovation development
occurs in various niches, current regime actors describe dynamics
towards implementation of niche developments and societal
landscape dynamics such as policy changes push towards this di-
rection. Nevertheless, it is not fully clear (yet) how this will affect
PIE. On the other hand, a transition to a new regime, with highly
restricted human pharmaceutical use and decimated livestock
sector, is expected to result in a substantial effect on PIE. The major
L. W€ohler, A.Y. Hoekstra, R.J. Hogeboom et al. Journal of Cleaner Production 277 (2020) 124350system and sectoral changes needed however, will require societal
pressure, governmental enforcement and financial incentives.
This study illustrates how, in the Dutch-German context, society
unequivocally prioritises human wellbeing over environmental
risks. A fundamental system change for human pharmaceuticals is
therefore not to be expected until this deeply rooted perception
changes. For the veterinary sector this hierarchy is less pronounced,
as landscape developments show. If these developments result in
the societal decision to reduce or renounce livestock production as
well as the consumption of animal products, this is (in time) ex-
pected to reduce animal related PIE.
Exploring alternative societal solutions to PIE while considering
the entire pharmaceutical lifecycle and emphasizing the societal
dimension is novel in the largely technology dominated discourse
on PIE. Requirements for and barriers to changes thus provide a
valuable contribution to society at large and decision makers in
particular when dealing with PIE.
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